Component
Human SGLT2-MAP17 transporter complex
Species, preparation, dose and limitations are retained on linked claims.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Cryo-EM placed phlorizin in an inward-facing human SGLT2-MAP17 complex, and biphasic kinetics suggested access from extracellular and intracellular sides.
Experimental context and source evidence
- dose
- Phlorizin and comparator synthetic inhibitors
- duration
- Acute
- evidence_access
- Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
- evidence_scope
- literature_reviewed; model-specific source-derived curation
- experimental_model
- Purified human SGLT2-MAP17 complex
- limitations
- A bound structure explains inhibition but does not establish human pharmacokinetics; synthetic inhibitors used different outward-facing poses.
- nutrient_topic
- Phlorizin chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Phlorizin
- organism
- Purified human SGLT2-MAP17 complex
- plain_language
- Cryo-EM placed phlorizin in an inward-facing human SGLT2-MAP17 complex, and biphasic kinetics suggested access from extracellular and intracellular sides.
- primary_references
- Transport and inhibition mechanism of the human SGLT2-MAP17 glucose transporter. (2024). https://pubmed.ncbi.nlm.nih.gov/38057552/ DOI: 10.1038/s41594-023-01134-0
- route
- Cell-free structural and transport analysis
- tissue
- Cryo-EM structures and inhibitor kinetics
Phlorizin: mechanism of action and interactions (2026-09-20) · lines 33–42
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Purified human SGLT2-MAP17 complex · source_derived_draft · unverified_draft
## phlorizin-sglt2-structure Cryo-EM placed phlorizin in an inward-facing human SGLT2-MAP17 complex, and biphasic kinetics suggested access from extracellular and intracellular sides. Model/species: Purified human SGLT2-MAP17 complex Tissue/system: Cryo-EM structures and inhibitor kinetics Exposure: Phlorizin and comparator synthetic inhibitors Route: Cell-free structural and transport analysis Duration: Acute Limits: A bound structure explains inhibition but does not establish human pharmacokinetics; synthetic inhibitors used different outward-facing poses. Primary reference: Transport and inhibition mechanism of the human SGLT2-MAP17 glucose transporter. (2024). https://pubmed.ncbi.nlm.nih.gov/38057552/ DOI: 10.1038/s41594-023-01134-0 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.